Results 171 to 180 of about 36,256 (261)

Durvalumab induced immune-related agranulocytosis after conversion surgery in a patient with intrahepatic cholangiocarcinoma: a case report [PDF]

Yoshihito Kitamura, Seiichi Shimizu, Shintaro Kuroda, Naruhiko Honmyo, Ryosuke Nakano, Hiroshi Sakai, Hiroyuki Tahara, Masahiro Ohira, Kentaro Ide, Tsuyoshi Kobayashi, Tatsuo Ichinohe, Hideki Ohdan   +11 more
openalex   +1 more source

LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers. [PDF]

Future Oncol
Ikeda M, Wörns MA, Akce M, Hsu C, Tebbutt NC, Casadei-Gardini A, Sah J, Farid-Kapadia M, Stirnadel-Farrant HA, Paskow MJ, Baur B, Melillo G, Schmidt J, Daktera A, Knox JJ.   +14 more
europepmc   +1 more source

Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis. [PDF]

Front Immunol
Zhang H, Yan G, Yan J, Zeng X.
europepmc   +1 more source

Biliary tract cancers: topaz-1 up-date, a practice changing study. [PDF]

Hepatobiliary Surg Nutr
Sarabi M, Artru P.
europepmc   +1 more source

Recurrent endometrial carcinoma with immune-mediated thrombocytopenia following durvalumab: A case report. [PDF]

Case Rep Womens Health
Sakakibara A, Nagai S, Shirane T, Sakai T, Fujioka Y, Hino M, Hattori Y, Kurahashi T.   +7 more
europepmc   +1 more source

G-CSF-producing pulmonary sarcomatoid carcinoma treated with chemoradiotherapy followed by durvalumab: a case report. [PDF]

Respir Med Case Rep
Hashimoto N, Kaira K, Uno T, Hashimoto K, Mouri A, Yamaguchi O, Imai H, Shojiguchi N, Homma T, Kagamu H.   +9 more
europepmc   +1 more source

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer [PDF]

Jung‐Min Lee, Junya Tabata, Tzu‐Ting Huang, Elena Giudice, Kristen R. Ibanez, Jayakumar R. Nair, Aanika Balaji, B. Brooke Solarz, Valentina Bolanos, Bernadette Redd, N Sato, Shraddha Rastogi, Sunmin Lee, Roshan L. Shrestha, Alexander Y. Mitrophanov, Stanley Lipkowitz, Kevin Conlon, Chien Chu Huang   +17 more
openalex   +1 more source

Successful Treatment of Nivolumab Plus Ipilimumab After Progression on Durvalumab Plus Tremelimumab in Advanced Hepatocellular Carcinoma: A Case Report. [PDF]

Cureus
Sasaki A, Kimura R, Okamoto R.
europepmc   +1 more source

Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies [PDF]

, 2018
Bradley, Jeffrey D, et al,
core   +1 more source

Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations [PDF]

, 2016

core   +1 more source